3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Small Cell Lung Carcinoma
2
Squamous Cell Carcinoma of Head and Neck
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Infections
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Gemcitabine
12
Mitomycin
6
Docetaxel
4
Radiotherapy
3
BCG Vaccine
3
tislelizumab
2
erdafitinib
2
dodecyl maltoside
2
disitamab vedotin
2
toripalimab
1
pemigatinib
1
pembrolizumab
1
monalizumab
1
linrodostat
1
enzalutamide
1
durvalumab
1
bicalutamide
1
avelumab
1
Watchful Waiting
1
Sugars
1
Postoperative Period
1
Pentosan Sulfuric Polyester
1
Nonsteroidal Anti-Androgens
1
Nivolumab
1
Metformin
1
Imiquimod
1
Hyaluronic Acid
1
High-Intensity Interval Training
1
Gels
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Non-Muscle Invasive Bladder Neoplasms
×
monalizumab
×
Clear all
NCT06503614
2026-04-08
ENHANCE
Hoosier Cancer Research Network
Phase 2
Recruiting
60 enrolled